TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04351737
Drug: Prednisolone Acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To reduce post-surgical pain and inflammation in patients who undergo bilateral pterygium surgery.
Study: NCT03439254
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally once daily.
Study: NCT02002650
Drug: Pre-ERCP rectal Indomethacin
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal Indomethacin was administrated within 30min before ERCP in all patients.
Study: NCT02002650
Drug: Post-operational Rectal Indomethacin
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.
Study: NCT01528124
Drug: LY3025876
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given as a subcutaneous injection
Study: NCT01528124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given as a subcutaneous injection
Study: NCT04145336
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.
Study: NCT03531970
Drug: 2% lidocaine with 1:80,000 epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthetic solution
Study: NCT03531970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02136693
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 g /day of inert compound for 180 days after STARR
Study: NCT01589237
Drug: LCQ908
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00824785
Drug: epirubicin, oxaliplatin, capecitabine (EOX)
Approvals — FDA: no, EMA: no, PMDA: no
Description: epirubicin 50mg/m(2) IV on day 1 oxaliplatin 130mg/m(2) IV on day 1 with hydration capecitabine 1250mg/m(2)/day PO in two divided doses continuously from days 1-21
Study: NCT02585869
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded capsule and tablets, once daily, 84 days
Study: NCT03929744
Drug: LY3502970
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT03929744
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT03929744
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT03029351
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo treatment weekly for 1 year in type 2 diabetes with micro-and macroalbuminuria
Study: NCT01441986
Drug: Pacebo 1 (placebo for Amantadine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talets for oral use; single dose.
Study: NCT01441986
Drug: Placebo 2 (fo Dextromethorphan)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsles for oral administration; single dose.
Study: NCT03307174
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03228901
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00863707
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT01893294
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00339456
Drug: HAART
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00816400
Drug: MEDI-575
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-575 as an IV infusion
Study: NCT03116737
Drug: Benzocaine Otic Solution
Normalized name: Benzocaine Otic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03116737
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00114413
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Used for both regular asthma control and as a rescue inhaler
Study: NCT00140192
Drug: creatine
Normalized name: Creatine
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03312283
Drug: QL1205
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravitreal injection of 0.5 mg (0.05 ml), Q4W, continuous administration for 3 times (D1, D29, D57)
Study: NCT00116883
Drug: GW685698X aqueous nasal spray
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03753659
Drug: Transarterial Chemoembolisation (TACE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to Investigator's choice, TACE using drug eluting beads can be performed combined with RFA, MWA or brachytherapy
Study: NCT04221399
Drug: DWP16001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, Once daily, Single dose
Study: NCT04221399
Drug: DWP16001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, Once daily, Multiple dose
Study: NCT01218893
Drug: Malarone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
Study: NCT02270918
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00913237
Drug: Desipramine Hydrochloride 50 mg Tablets (Cord Laboratories)
Normalized name: desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00913237
Drug: Desipramine Hydrochloride 50 mg Tablets (Merrell Dow Pharmaceuticals, Inc)
Normalized name: desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02240667
Drug: Vitamin K antagonists
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: International Normalized Ratio (INR) 2-3
Study: NCT04318067
Drug: Melatonin 3 mg
Normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin 3 mg is given ones a day - at bedtimes for 6 month
Study: NCT00461032
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to montelukast QD for 8 weeks
Study: NCT01837745
Drug: rhTSH stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections of rhTSH (0.9 mg) on two consecutive days on LT4 treatment
Study: NCT04067648
Drug: Sufentanil Injection
Normalized name: sufentanil Injection
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: three doses of sufentanil was intravenously given during anesthesia induction
Study: NCT00238147
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00182663
Drug: clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01143779
Drug: FLT-PET
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLT-PET scan uses the FLT solution (dosage of FLT in range between 1 and 10 mCi) with imaging performed 60-90 minutes after FLT intravenous injection.
Study: NCT02204943
Drug: Administration of radium-223
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive radium-223 treatment for their disease as standard of care in this protocol. They will be receiving this treatment regardless of their participation in this protocol.
Study: NCT02039258
Drug: CANA/MET XR FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) tablet of 150 mg/1,000 mg
Study: NCT00001781
Drug: CGP 77116
Normalized name: Leucoflex CGP KIT
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01563523
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy in conjunction with three single doses of placebo administered over a 3 hour period. Administered once the subject has received 8 units of PRBC
Study: NCT00449553
Drug: Pioglitazone and sulphonylurea
Normalized name: glimepiride and pioglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 15 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.
Study: NCT00449553
Drug: Pioglitazone and sulphonylurea
Normalized name: glimepiride and pioglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.
Study: NCT04458363
Drug: Standard COVID-19 therapies
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: If clinical status permits, administration of additional COVID-19 therapies should be delayed 48 hours or more from CP infusion completion. Supportive care will be administered by best clinical practice.
Study: NCT00277706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo; self administration for 6 weeks
Study: NCT03112564
Drug: Sevoflurane 8% + Intravenous fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane 8% + Intravenous fentanyl was the regimen used for induction and maintenance of anesthesia
Study: NCT04288999
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy: CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV~CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)~mFOLOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.~Capecitabine: 2000 mg/m2/day, twice daily, days 1-14~5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours
Study: NCT03558373
Drug: Immunosuppressive
Normalized name: Immunosuppressive acidic protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive therapies
Study: NCT00008073
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03046693
Drug: Group B placebo oral tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be repackaged and given to Group B for 60 days
Study: NCT02729285
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: On operation day, the patients were randomly assigned to receive placebo 30 min before scleral buckle surgery.
Study: NCT01590082
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase I Starting Dose: 200 mg by mouth twice a day on Day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts)~Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I.
Study: NCT01054170
Drug: AZD9668
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 30 mg oral tablets twice daily (bid) for 12 weeks
Study: NCT01054170
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x matched placebo to oral tablet twice daily (bid) for 12 weeks
Study: NCT01237587
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02851485
Drug: GLPG1972 600 mg oral tablet fasted
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosing after overnight fasting
Study: NCT02851485
Drug: GLPG1972 600 mg oral tablet fed
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosing after high-fat high-calorie breakfast
Study: NCT00279032
Drug: GW406381
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00456885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily injection of placebo
Study: NCT02045056
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02968082
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch will be applied under the ear of the opposite side of operation, at 9 p.m. of the day before the operation day. Nausea will be assessed by Visual Analogue Scale (VAS) immediate after arrival at a recovery room and the ward. After that, nausea will be continuously assessed every 4 hour (4hr, 8hr, 12hr, 16hr, 20hr, and 24hr after surgery) and a number of vomiting will also be counted. Basic clinical characteristics and the number of antiemetic administration will be identified through medical records.
Study: NCT01764841
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.
Study: NCT00746551
Drug: Ferli-6® (Continental Pharm co., ltd.)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the O-group, women had to take 3 ferrous fumarate tablets (Ferli-6®) everyday with a total of 200 mg of elemental iron per day from 33 weeks gestation until delivery. Emphasizing and monitoring for compliance to the treatment protocol were carried out.
Study: NCT00746551
Drug: Venofer® (Vifor AG, St. Gallen, Switzerland)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women in the IV-group received 500 mg iron sucrose (Venofer®, Vifor International AG, St. Gallen, Switzerland) divided into three weekly administrations. Two doses of 200 mg iron sucrose were given at 33 and 34 weeks gestation while the remaining (100 mg) was infused at gestation of 35 weeks. Thereafter, women in this group received no further iron therapy until delivery. In preparation, 200 mg of iron sucrose was diluted into 100 ml of 0.9% saline solution.
Study: NCT03436121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this study, patients in the active comparator group will receive midazolam first, then placebo. A placebo is an inactive solution that looks like the study drug, but contains no active ingredients.
Study: NCT02075541
Drug: NaCl Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
Study: NCT01134120
Drug: LY2784544
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2784544 will be supplied as a capsule. The study drug will be taken by mouth daily while the patient is on study. In this study, different patients will be treated at different doses of LY2784544 until reaching the highest dose that patients can tolerate.
Study: NCT01579578
Drug: AZD8931
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg, oral dose twice daily
Study: NCT01579578
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, oral dose twice daily
Study: NCT01302691
Drug: losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E)
Normalized name: hydrochlorothiazide / losartan potassium Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet, containing 50 mg losartan potassium, 12.5 mg hydrochlorothiazide, and 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
Study: NCT01302691
Drug: Placebo to MK-0954E
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet, containing placebo, orally, once daily, for 8 weeks.
Study: NCT04169230
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administration lactose placebo tablet
Study: NCT01270971
Drug: AN2690 Topical Solution, 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: AN2690 Topical Solution, 5%, applied once daily for 48 weeks
Study: NCT01270971
Drug: Solution Vehicle
Normalized name: Flavor Sweet Oral Solution Vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
Study: NCT02015663
Drug: Tobramycin Inhalation Powder
Normalized name: Tobramycin Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin Inhalation Powder 112 mg (four 28-mg capsules) taken via inhaler once or twice a day, depending on study arm
Study: NCT00136916
Drug: Inhaled Insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin with dose adjusted according to premeal blood glucose
Study: NCT00386269
Drug: Codeine Phosphate Analgesia
Normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01030406
Drug: 40/0mg taken first
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8x Oxycodone/Niacin 5/0mg tablets All arms taken with a 48 hour washout between doses
Study: NCT01030406
Drug: 80/0mg taken first
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8x Oxycodone/Niacin 10/0mg tablets All arms taken with a 48 hour washout between doses
Study: NCT01030406
Drug: 40/240mg taken first
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8x Oxycodone/Niacin 5/30mg tablets All arms taken with a 48 hour washout between doses
Study: NCT01030406
Drug: 80/480mg taken first
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8x Oxycodone/Niacin 10/60mg tablets All arms taken with a 48 hour washout between doses
Study: NCT01030406
Drug: 0/0mg taken first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo All arms taken with a 48 hour washout between doses
Study: NCT00136916
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin with dose adjusted according to premeal blood glucose
Study: NCT00006085
Drug: CP-609,754
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03790293
Drug: corticosteroids'therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient was enrolled into the RITUXIMAB 3 study in the arm Patient was enrolled into the RITUXIMAB 3 study in the arm standard corticosteroid
Study: NCT00417196
Drug: QAX576
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01458067
Drug: GSK2636771
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT01614535
Drug: up-and-down method to find out effective concentration of remifentanil for preventing cough during emergence
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Targeted effect-site TCI remifentanil for preventing cough effectively during emergence from general anesthesia. For effect-site TCI of remifentanil, a TCI pump was used and pump operation was based on Minto and colleagues' pharmacokinetic model. By Dixon's up-and-down method, the predetermined effect-site concentration(Ce) of remifentanil was determined according to the cough response of the previous patient. The initial target Ce of remifentanil for the first patient was 2.0 ng/ml. If the patients did not cough throughout the peri-extubation period, the predetermined Ce of remifentanil for the subsequent patient was decreased by 0.4 ng/ml. If the patient coughed anytime around extubation, the predetermined Ce for the subsequent patient was increased by 0.4 ng/ml. The stopping rule, as well as for the requirement of at least six turning points in the same direction of the sequential allocation response graph, required the recruitment of more than 20 patients.
Study: NCT00334854
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02822144
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00758446
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules, p.o, daily, 14 days
Study: NCT04232839
Drug: BI 894416 Formulation A2
Normalized name: PROCYANIDIN A2
Approvals — FDA: no, EMA: no, PMDA: no
Description: T1 - One single dose of 62.5 milligram (1 tablet) BI 894416 Formulation A2, extended release (ER) tablet (fast release rate, FRR) taken orally with 240 mL of water after an overnight fast of at least 10 hours.
Study: NCT00249834
Drug: Recombinant human chorionic gonadotrophin (r-hCG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: When at least 1 follicle greater than or equal to (\>=) 18 millimeter (mm) and 2 follicles \>=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.
Study: NCT03768713
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insomnia subjects will take a nightly pill of 20 mg placebo for eight weeks.
Study: NCT02187783
Drug: LEE011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug was provided in 200 mg and 50 mg hard gelatin capsules to be taken orally
Study: NCT03115034
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients under CEA taking 6mg/day melatonin orally from 3 days before operation to 3 days after operation.
Study: NCT03115034
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients under CEA taking placebo orally from 3 days before operation to 3 days after operation.
Study: NCT00177034
Drug: Narrow Band UVB Treatment
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02579629
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be administered as a single bolus dose of 8ml of normal saline followed by an infusion of normal saline using the On-Q® elastomeric pump. The bolus dose of 8ml of normal saline will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr normal saline for 72 hours post-operatively.
Study: NCT00569985
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02548195
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine 1250 mg/m2, twice daily for two weeks plus one week rest for 8 cycles in total.
Study: NCT00643448
Drug: AZD1305
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1305 loading dose 250 mg + 125 mg evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2
Study: NCT00643448
Drug: AZD1305
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1305 loading dose 500 mg + placebo evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2
Study: NCT00643448
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo corresponding to AZD1305 loading dose + evening dose on Study Day 1, maintenance dose twice daily from Study Day 2
Study: NCT01130272
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo oral tablets twice daily.
Study: NCT00304525
Drug: RAF265
Approvals — FDA: no, EMA: no, PMDA: no
Description: A liquid nonaqueous oral formulation. Switched to a tablet formulations with was 60% bioavailable, relative to the liquid at 50mg dose. The liquid dose will be multiplied by a factor of 1.67 to achieve a comparable tablet dose. Tablets are available in 10mg and 50mg strengths.